TP53 and endometrial cancer: Thus, the association between survivin and the two tumor suppressor genes, PTEN and TP53, is likely to be an attractive molecular therapeutic target, as mutation of these two genes is the most common gene mutation documented in endometrial cancer (52, 53, 54).